Industry Focus

Takeda may buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.

Direct download: 20180404_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT